Craving clinical trials at UCSD
1 in progress, 0 open to eligible people
Advancing VR-based Attentional Bias As a Biomarker for Tobacco Use Disorder
Sorry, not yet accepting patients
The proposed project will include enrollment of 200 daily tobacco cigarette users, ages 22+, from the San Diego community. Participants will be assessed on the VR Nicotine Cue Exposure paradigm then randomized (stratified on age and sex) to receive varenicline (target dose 1mg twice daily) or placebo (n per group=100; total N=200). Following eight days of titration, participants will be assessed again on the VR Nicotine Cue Exposure paradigm. They will then be followed via mobile assessments for eight days on target dose of varenicline, and 30-days post assessment by phone, to assess short-term nicotine use behaviors.
San Diego, California
Our lead scientists for Craving research studies include Kelly Courtney.
Last updated: